NASDAQ:NBSE NeuBase Therapeutics (NBSE) Stock Price, News & Analysis → Trump’s last act as President (From Porter & Company) (Ad) Free NBSE Stock Alerts $0.42 +0.00 (+0.10%) (As of 05:12 PM ET) Add Compare Share Share Today's Range$0.42▼$0.4250-Day Range$0.40▼$1.0752-Week Range$0.39▼$4.80Volume1,183 shsAverage Volume194,025 shsMarket Capitalization$1.56 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Get NeuBase Therapeutics alerts: Email Address Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About NeuBase Therapeutics Stock (NASDAQ:NBSE)NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.Read More NBSE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NBSE Stock News HeadlinesApril 6, 2024 | finanznachrichten.deNeuBase Therapeutics, Inc.: NeuBase Therapeutics Announces Receipt of Notice from NasdaqApril 5, 2024 | globenewswire.comNeuBase Therapeutics Announces Receipt of Notice from NasdaqMay 1, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.March 27, 2024 | msn.comWhy Neubase Therapeutics (NBSE) Shares Are NosedivingMarch 26, 2024 | msn.comNeuBase Therapeutics, ABVC BioPharma, Stoke Therapeutics among healthcare moversMarch 26, 2024 | investorplace.comWhy Is NeuBase Therapeutics (NBSE) Stock Down 58% Today?March 25, 2024 | bizjournals.comNeuBase Therapeutics sets shareholder meeting on dissolution planFebruary 26, 2024 | edition.cnn.comNeuBase Therapeutics IncMay 1, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.February 20, 2024 | finance.yahoo.comNeuBase Therapeutics, Inc. (NBSE)January 20, 2024 | ca.finance.yahoo.comNeuBase Therapeutics Inc (O7P.BE)December 22, 2023 | bizjournals.comCMU halts licensing agreement with NeuBase TherapeuticsNovember 27, 2023 | finance.yahoo.comPsychemedics Corporation Appoints Daniella Mehalik as VP - FinanceNovember 6, 2023 | morningstar.comNeuBase Therapeutics Inc NBSEOctober 6, 2023 | finance.yahoo.comNeuBase Therapeutics, Inc. (NBSE.MX)September 12, 2023 | benzinga.comMassive Insider Trade At NeuBase TherapeuticsSeptember 12, 2023 | msn.comNeuBase falls after largest shareholder disposes of part stakeSeptember 8, 2023 | finance.yahoo.comNeuBase Therapeutics Issues Statement Regarding Filing By ShareholderSeptember 6, 2023 | markets.businessinsider.comWhy Is NeuBase Therapeutics (NBSE) Stock Up 19% Today?August 16, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: NeuBase Therapeutics (NBSE) and Centessa Pharmaceuticals (CNTA)August 6, 2023 | fool.comNeuBase Therapeutics (NASDAQ: NBSE)August 3, 2023 | finance.yahoo.comNeuBase Therapeutics to Explore Strategic AlternativesAugust 1, 2023 | bizjournals.comPittsburgh biotech firm amends stock incentive planJune 30, 2023 | finance.yahoo.comNeuBase Announces Closing of $5 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq RulesJune 29, 2023 | finance.yahoo.comNeuBase Presents Non-Human Primate Data Illustrating Stealth Editors™ are Non-Immunogenic, Opening the Door to RedosingJune 28, 2023 | finance.yahoo.comNeuBase Announces $5 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq RulesJune 14, 2023 | finanznachrichten.deNeuBase Therapeutics, Inc.: NeuBase Announces 1-for-20 Reverse Stock SplitSee More Headlines Receive NBSE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeuBase Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings12/23/2021Today5/01/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:NBSE CUSIPN/A CIK1173281 Webwww.neubasetherapeutics.com Phone(164) 645-1790FaxN/AEmployees37Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($7.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,370,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-99.74% Return on Assets-60.13% Debt Debt-to-Equity RatioN/A Current Ratio2.87 Quick Ratio2.87 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$11.04 per share Price / Book0.04Miscellaneous Outstanding Shares3,750,000Free Float3,456,000Market Cap$1.58 million OptionableNot Optionable Beta0.83 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Todd P. Branning (Age 54)Interim CEO, CFO & Secretary Comp: $427.44kDr. Dietrich A. Stephan Ph.D. (Age 54)Founder, President & Director Comp: $836.58kKey CompetitorsInMed PharmaceuticalsNASDAQ:INMHistogenNASDAQ:HSTOPanbela TherapeuticsNASDAQ:PBLALucy Scientific DiscoveryNASDAQ:LSDIGalmed PharmaceuticalsNASDAQ:GLMDView All CompetitorsInsidersCorp SymetryxSold 129,108 sharesTotal: $185,915.52 ($1.44/share)Corp SymetryxSold 3,376 sharesTotal: $4,861.44 ($1.44/share)Corp SymetryxSold 74,852 sharesTotal: $134,733.60 ($1.80/share)Corp SymetryxBought 61,076 shares on 9/1/2023Total: $59,854.48 ($0.98/share)View All Insider Transactions NBSE Stock Analysis - Frequently Asked Questions How have NBSE shares performed in 2024? NeuBase Therapeutics' stock was trading at $0.7401 at the beginning of the year. Since then, NBSE stock has decreased by 43.8% and is now trading at $0.4160. View the best growth stocks for 2024 here. Are investors shorting NeuBase Therapeutics? NeuBase Therapeutics saw a decline in short interest during the month of April. As of April 15th, there was short interest totaling 24,500 shares, a decline of 83.6% from the March 31st total of 149,100 shares. Based on an average daily trading volume, of 230,400 shares, the short-interest ratio is presently 0.1 days. Currently, 0.8% of the company's shares are sold short. View NeuBase Therapeutics' Short Interest. When is NeuBase Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our NBSE earnings forecast. How were NeuBase Therapeutics' earnings last quarter? NeuBase Therapeutics, Inc. (NASDAQ:NBSE) issued its earnings results on Thursday, December, 23rd. The company reported ($4.20) EPS for the quarter, topping analysts' consensus estimates of ($4.60) by $0.40. When did NeuBase Therapeutics' stock split? NeuBase Therapeutics shares reverse split on the morning of Thursday, June 15th 2023. The 1-20 reverse split was announced on Thursday, June 15th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of NeuBase Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other NeuBase Therapeutics investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Ovid Therapeutics (OVID), Advanced Micro Devices (AMD), Enterprise Products Partners (EPD), Flexion Therapeutics (FLXN), Pfizer (PFE), VBI Vaccines (VBIV), AbbVie (ABBV) and Aravive (ARAV). How do I buy shares of NeuBase Therapeutics? Shares of NBSE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NBSE) was last updated on 5/1/2024 by MarketBeat.com Staff From Our PartnersElon’s New Device is About to Shock the WorldInvestorPlace😱 This phenomenon is smashing regular market gainsMillPubYour bank is lying to you.MyBankTrackerDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market InsidersPOTUS in ‘25 Not Biden/Trump, ButThe Freeport SocietyForget Nvidia. This is the future of AIPorter & CompanyBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuBase Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
